Cancer: Principles & Practice of Oncology

• Vincent T DeVita, Jr. MD
• Amy and Joseph Perella Professor of Medicine, Yale Comprehensive Cancer Center and Smilow Cancer Hospital at New Haven, New Haven, CT

• Theodore S Lawrence MD, PhD
• Isadore Lampe Professor and Chair, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

• Steven A Rosenberg MD, PhD
• Chief of Surgery, National Cancer Institute, National Institutes of Health; Professor of Surgery, Uniformed Services University of the Health Sciences School of Medicine, Bethesda, MD; Professor of Surgery, George Washington University School

• Edition: Volume 2
• Product Format: Hardbound
• ISBN: 9781451142693
• Trim Size: 8 x 10
• Pages: 560
• Volumes: 2
• Pub Date: Jun 16, 2011
• Weight: 3.0

Section Editors iii Contributing Authors iv Preface xv P TRI ART 1:PLE-NEGATIVE BREAST CANCER1. Epidemiology to Treatment.........................1 Triple-Negative Breast Cancer: FromCLIFFOR D A. HUDIS2. and Basal Breast Cancers?..........................3 What is the Difference between Triple-NegativeMELANIE D. SEAL AND STEPHEN K. CHIA3. 10,000 Feet..............................................8 Triple-Negative Breast Cancers: A View fromMAN DIRA RAY AND BLASE N. POLITE4. Triple-Negative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker?......................................14 Epidermal Growth Factor Receptor inMONIKA L. BURNESS, TATYANA A. GRUSHKO, AN DOLUFUNMILAYO I. OLO PADE5. Antiangiogenic Agents ............................. 24 Triple-Negative Breast Cancer: Role ofSALLY GREENBERG AN D HOPE S. RUGO6. Tumor Suppression: A Repair-Centric Perspective.............................................30 BRCA Gene Structure and Function inCONLETH G. MUR PHY ANDMARY ELLEN MOYNAHAN 7. Triple-Negative Breast Cancer...................39 Poly (ADP-Ribose) Polymerase Inhibitors inELIZABETH A. COMEN AN D MARK ROBSON8. Specific Chemotherapy Agents...................44 Triple-Negative Breast Cancer: Role ofSTEVEN J. ISAKOFF 9. Androgen Receptor ................................. 53 Triple-Negative Breast Cancer: Role of theAYCA GUCAL P AND TIFFANY A. TRAINAP LOCAL THERA OF LIVER METASTASES ART 2:PIES IN THE TREATMENT10. Treatment of Liver Cancer........................57 Introduction to Local Therapies in theWILLIAM D. ENSMINGER AND ALFRED E. CHANG11. Hepatic Imaging for Metastatic Disease.......59P ETER S. LIU AND ISAAC R. FRANCIS12. Metastasis: Evolving Role in the Setting of Improving Systemic Therapies and Ablative Treatments in the 21st Century..................69 Surgical Treatment of Hepatic ColorectalKAORI ITO, ANAN AN D GOVINDARAJAN, HIROMICHI ITO,D YUMAN FONG13. Hepatic Malignancies...............................77 Thermal Ablative Therapies for SecondarySKYE C. MAYO AN D TIMOTHY M. PAWLIK14. Liver Cancer...........................................84 Focused Ultrasound as a Local Therapy forKRISZTINA FISCHER, WLA DYSLAW GEDROYC, ANDFERENC A. JOLESZ 15. Patients with Resectable Liver Metastases....91 The Role of Chemotherapy in ManagingTHORVAR MICHAEL L. KEN DUR R. HALFDANARSON,DRICK, AND AXEL GROTHEY16. via the Operative and Percutaneous Techniques for Patients with Isolated and Unresectable Liver Metastases...................98 Development of Isolated Hepatic PerfusionH. RICHAR D ALEXANDER, JR., ANDCAROLINE C. BUTLER 17. Infusion Pumps.....................................108 Implanted Hepatic ArterialMARGARET K. CALLAHAN AN DNANCY E. KEMENY 18. Management of Liver Metastases ............. 116 Emerging Role of Radiotherapy in theANAN D SWAMINATH AND LAURA A. DAWSON19. Metastatic Liver Cancer..........................122 Chemoembolization for Primary andELENI LIA PI AND JEAN-FRANCOIS H. GESCHWIND20. for Primary and Metastatic Hepatic Malignancies ........................................129 Radioembolization (Yttrium-90 Microspheres)AN DREW S. KENNEDY AND RIAD SALEMP CHEMOTHERA CANCER ART 3:PY FOR COLORECTAL21. Colorectal Cancer..................................143 Introduction to Chemotherapy forE DWARD CHU22. Biology of Colorectal Cancer...................144MUHAMMA D WASIF SAIF AND EDWARD CHU23. Advances and Future Directions...............150 Stage II and Stage III Colon Cancer: TreatmentBENO\u00c2IT ROUSSEAU, BENOIST CHIBAU JEAN-BA CHRISTO THIERRY AN DEL,PTISTE BACHET, ANNETTE K. LARSEN,PHE TOURNIGAND, CHRISTOPHE LOUVET,DRE\u00b4 , AND AIMERY DE GRAMONT24. Gene Profiling in Early Stage Disease ........ 158RACHEL MI HAITHAM AL SALAMA, AN DGLEY, KAKIL RASUL,D DAVID J. KERR25. Chemotherapy for Colon Cancer..............162 Optimal Delivery of CytotoxicLAURA RAFTERY AN D RICHARD M. GOLDBERG26. Growth Factor Therapies with Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer..................................168 Integration of Anti-Vascular EndothelialSUILANE COELHO RIBEIRO OLIVEIRA, KARIME KALIL MACHA P DO, JORGE SABBAGA, ANDAULO M. HOFF27. Receptor Therapies with Cytotoxic Chemotherapy......................................174 Integration of Anti-Epidermal Growth FactorCE\u00b4 SAR SERRANO, BEN MARKMAN, AN DJOSE P TABERNERO28. Colorectal Cancer..................................183 Treatment of Liver-Limited MetastaticJOLEEN M. HUBBAR D AND STEVEN R. ALBERTS29. with Colorectal Cancer...........................189 Chemotherapy for the Elderly PatientD EREK G. POWER AND STUART M. LICHTMAN30. Cancer.................................................201 Combined Modality Therapy for RectalBRUCE D. MINSKY, CLAUS RO\u00a8 EDEL, ANDVINCENZO VALENTINI 31. Metastatic Colorectal Cancer...................210 Molecular Markers in the Treatment ofP ETER M. WILSON, MELISSA J. LABONTE, ANDHEINZ-JOSEF LENZ 32. Metastatic Colorectal Cancer...................221 Novel Agents in the Treatment ofSTE AIK CHOON TAN, AN PHEN LEONG, WELLS A. MESSERSMITH,D S. GAIL ECKHARDTP IMMUNOTHERA ART 4:PY OF CANCER33. of Cancer.............................................231 Introduction for ImmunotherapyJEFFREY S. WEBER 34. Chemoimmunotherapy...........................232LEISHA A. EMENS 35. Cellular Vaccine Approaches ................... 241D UNG T. LE, DREW M. PARDOLL, ANDELIZABETH M. JAFFEE 36. the Next Advance? ................................ 248 Immune Regulatory Antibodies: Are TheyJE DD D. WOLCHOK, ARVIN S. YANG, ANDJEFFREY S. WEBER 37. Relevant?.............................................255 Dendritic Cells: Are They ClinicallyKAROLINA JOSE PALUCKA, HIDEKI UENO, LEE ROBERTS,PH FAY, AND JACQUES BANCHEREAU38. Redirected to the Site of the Tumor?.........262 Chemokines: Can Effector Cells BeSTEVEN M. AN DUBINETT, JAY M. LEE, SHERVEN SHARMA,D JAMES J. MUL\u00b4E39. to Redirect Effector Cell Specificity...........273 Adoptive Cell Therapy: Genetic ModificationRICHAR D A. MORGAN, MARK E. DUDLEY, ANDSTEVEN A. ROSENBERG 40. Suppression of T-Cell Immunity...............280 Regulatory T Cells: OvercomingTATIANA N. GOLOVINA AN D ROBERT H. VONDERHEIDE41. in Human Cancer..................................286 Myeloid-Derived Suppressor CellsSRINIVAS NAGARAJ AN D DMITRY I. GABRILOVICH42. Immune Suppressor?..............................292 Indoleamine 2,3-Dioxygenase: Is It anHATEM SOLIMAN, MELANIE ME DIAVILLA-VARELA, ANDSCOTT ANTONIA 43. Inhibition and Immunotherapy in Melanoma............................................298 Interface of Signal TransductionAMBER L. SHA DA, KERRINGTON R. MOLHOEK, ANDCRAIG L. SLINGLUFF, JR. 44. T-Cell Clones........................................305 Adoptive Therapy Using Antigen-SpecificCASSIAN YEE 45. Use in Adoptive Immunotherapy..............312 Artificial Antigen-Presenting Cells forCAMERON J. TURTLE AN D STANLEY R. RIDDELL46. Good Adjuvants?...................................320 Toll-Like Receptor Agonists: Are TheySACHA GNJATIC, NIKHIL B. SAWHNEY, AN DNINA BHAR DWAJ47. Candidate Immune Modulators in Immune Therapies for Cancer ............................. 330 Novel Gamma-Chain Cytokines asNATASHA M. FEWKES AN D CRYSTAL L. MACKALL48. Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy..........................337 Gene Signature in Melanoma Associated withTHOMAS F. GAJEWSKI, JAMILA LOUAHE D, ANDVINCENT G. BRICHAR DP THE ROLE OF THE ONCOLOGIST IN ART 5:P ALLIATIVE CARE49. Palliative Care.......................................343 The Role of the Oncologist inNATHAN CHERNY 50. Palliative Care.......................................344 The OncologistÆs Role in DeliveringNATHAN CHERNY 51. Teams Improve Outcomes for Cancer Patients and Their Families?....................355 What Is the Evidence That Palliative CareIRENE